BioLineRx Ltd. (NASDAQ:BLRX) Sees Large Increase in Short Interest

BioLineRx Ltd. (NASDAQ:BLRX) saw a large growth in short interest during the month of September. As of September 15th, there was short interest totalling 179,200 shares, a growth of 28.7% from the August 31st total of 139,200 shares. Based on an average daily volume of 270,600 shares, the short-interest ratio is presently 0.7 days.

Hedge Funds Weigh In On BioLineRx

An institutional investor recently bought a new position in BioLineRx stock. PVG Asset Management Corp acquired a new stake in shares of BioLineRx Ltd. (NASDAQ:BLRX) in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund acquired 61,840 shares of the biotechnology company’s stock, valued at approximately $97,000. BioLineRx accounts for approximately 0.5% of PVG Asset Management Corp’s holdings, making the stock its 29th largest holding. PVG Asset Management Corp owned 0.09% of BioLineRx as of its most recent SEC filing. 1.56% of the stock is owned by institutional investors.

BioLineRx Trading Down 1.6 %

Shares of NASDAQ:BLRX traded down $0.01 during midday trading on Friday, reaching $0.62. The company’s stock had a trading volume of 145,924 shares, compared to its average volume of 333,238. The firm has a market cap of $49.56 million, a price-to-earnings ratio of -0.82 and a beta of 1.46. The business has a 50 day moving average price of $0.69 and a 200 day moving average price of $0.72. BioLineRx has a 1 year low of $0.51 and a 1 year high of $2.03. The company has a quick ratio of 1.49, a current ratio of 1.61 and a debt-to-equity ratio of 1.34.

BioLineRx (NASDAQ:BLRX) last posted its quarterly earnings data on Thursday, August 15th. The biotechnology company reported $0.01 EPS for the quarter, beating analysts’ consensus estimates of ($0.08) by $0.09. The company had revenue of $5.39 million for the quarter, compared to analyst estimates of $3.93 million. Research analysts forecast that BioLineRx will post -0.25 EPS for the current year.

Analyst Ratings Changes

Separately, StockNews.com upgraded shares of BioLineRx from a “sell” rating to a “hold” rating in a research report on Monday, June 3rd.

About BioLineRx

BioLineRx Ltd., a commercial stage biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma.